Physiomics PLC
PYC
Company Profile
Business description
Physiomics PLC is a United Kingdom-based firm that provides consulting services to biopharmaceutical companies and research institutes in the areas of outsourced modelling and simulation (quantitative pharmacology), biometrics, and data science (bioinformatics). Its business activities involve the use of industry-standard technologies and a proprietary technology platform called Virtual Tumour. The company has three service lines: Biometrics, Modelling and Simulation (Quantitative Pharmacology) and Personalised Medicine. It derives revenue from the UK, the European Union and Switzerland.
Contact
140 Eastern Avenue
Bee House, Milton Park
AbingdonOX14 4SB
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
10
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,908.82 | 72.45 | -0.91% |
| DAX 40 | 22,916.77 | 382.12 | -1.64% |
| Dow JONES (US) | 46,196.17 | 369.57 | -0.79% |
| FTSE 100 | 10,393.58 | 28.79 | 0.28% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,612.97 | 227.98 | -1.04% |
| Nikkei 225 | 52,463.27 | 1,276.41 | -2.38% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,527.28 | 48.04 | -0.73% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |